Monitor the October 16 special meeting vote and the $13M minimum cash condition. Post-merger, focus shifts to Eos's preclinical data for PTC-2105 and its ability to raise additional capital. The controlled company structure limits minority protections.
Price Chart
Executive Summary
Pulmatrix is asking stockholders to vote on a reverse merger with Eos SENOLYTIX, a preclinical biotech developing mitochondrial-targeted gerotherapeutics. Existing Pulmatrix holders will own only ~6% of the combined company, which will be controlled by Eos's founder. The merger is a de facto acquisition of Pulmatrix's public shell by Eos, with Pulmatrix's legacy business continuing as a minor stream.
Key Financial Metrics
Key Facts
- Pulmatrix stockholders will own ~6% of the combined company on a fully-diluted basis; Eos securityholders will own ~94%.
- Eos is a preclinical-stage biotech with no revenue and a lead candidate (PTC-2105) still in IND-enabling studies.
- SENOTHERAPEUTIX, Inc. will own >50% of the combined company's voting power, making it a controlled company.
- The combined company will trade under new ticker MTXL; Pulmatrix's current ticker PULM will be replaced.
- Pulmatrix's board unanimously recommends a FOR vote on all proposals; special meeting is October 16, 2026.
- Eos must receive at least $13M in gross cash proceeds at closing as a condition to the merger.
- Pulmatrix's financial advisor Gemini Valuation Services opined the exchange ratio is fair from a financial point of view to Pulmatrix holders.
- Pulmatrix stockholders have no appraisal rights in connection with the merger.
- CEO RSUs for up to 13M shares of combined company stock were granted to an entity controlled by Eos's CEO.
- Pulmatrix's stock closed at $1.67 on September 24, 2026, down from $2.12 on the last trading day before the merger announcement.
Financial Impact
Existing Pulmatrix holders' ownership diluted to ~6% of combined entity; implied value of Pulmatrix's stake is ~$7.85M based on a $100M pre-money valuation of Eos plus $19M in anticipated capital. No cash consideration paid to Pulmatrix stockholders.
Risk Factors
- Merger may not close if conditions (stockholder approval, Nasdaq listing, $13M financing) are not met.
- If merger fails, Pulmatrix may need to liquidate, likely resulting in near-zero value for stockholders.
- Combined company has no approved products and will require substantial additional capital.
- Controlled company structure concentrates voting power with Eos's founder, reducing minority shareholder influence.
- CEO RSUs of up to 13M shares represent significant potential dilution for other stockholders.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001493152-26-044341 |
| Document: formdefm14a.htm | 0001493152-26-044341 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | EFFECT | $1.48 | awaiting T+5 | — | $1.51 (−2.03%) |
Oct 22, 2026 5d ago | 425 | $1.42 | awaiting T+5 | — | $1.51 (+6.34%) |
Oct 13, 2026 14d ago | 425 | $1.38 $1.43 | ▲ +3.62% | ▲ +4.77% | $1.51 (+9.42%) |
Oct 7, 2026 19d ago | DEFA14A | $1.53 $1.41 | ▼ −7.67% | ▼ −7.39% | $1.51 (−1.12%) |
Oct 2, 2026 24d ago | S-3/A | $1.48 $1.43 | ▲ +3.38% | ▲ +3.80% | $1.51 (−2.03%) |
Sep 28, 2026 29d ago | EFFECT | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.51 (+5.03%) |
Sep 25, 2026 4w ago | DEFM14A | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.51 (+5.03%) |
Sep 23, 2026 4w ago | S-4/A | $1.67 $1.54 | ▼ −7.78% | ▼ −7.37% | $1.51 (−9.58%) |
Sep 22, 2026 4w ago | 425 | $1.69 $1.52 | ▼ −9.79% | ▼ −9.12% | $1.51 (−10.39%) |
Sep 17, 2026 5w ago | S-4/A | $1.44 $1.61 | ▲ +11.81% | ▲ +10.54% | $1.51 (+4.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers